[{"orgOrder":0,"company":"NeoPhore","sponsor":"CRT Pioneer Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"NeoPhore \/ CRT Pioneer Fund","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ CRT Pioneer Fund"},{"orgOrder":0,"company":"NeoPhore","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NeoPhore \/ The Institute of Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"NeoPhore","sponsor":"Sixth element capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"NP1867","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"NeoPhore \/ Sixth Element Capital","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ Sixth Element Capital"},{"orgOrder":0,"company":"NeoPhore","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NeoPhore \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals by NeoPhore

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : NeoPhore will explore novel biology associated with the DNA MMR pathway in cancer and progress its pre-clinical studies of small molecule drugs targeting novel proteins across the MMR pathway.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Undisclosed

                          Deal Type : Series B Financing

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The net proceeds will be used to progress NeoPhore's lead canditate, NP1867, an oral, small molecule, first-in-class MMR inhibitor, through early pre-clinical development in solid tumours.

                          Brand Name : NP1867

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 01, 2024

                          Lead Product(s) : NP1867

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Sixth element capital

                          Deal Size : $39.5 million

                          Deal Type : Series B Financing

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The collaboration will use NeoPhore's proprietary small molecule inhibitors of DNA mismatch repair to investigate single agent activity against tumours with defined genetic backgrounds.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 18, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : The Institute of Cancer Research

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The additional funding will be used to progress NeoPhore's expanding pipeline of drugs, encompassing multiple biological targets and modalities of treatment, to the start of IND-enabling studies in 2024.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 19, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : CRT Pioneer Fund

                          Deal Size : $28.5 million

                          Deal Type : Series B Financing

                          blank